Rosetta Genomics Ltd. has received regulatory approval for their diagnostic test using MicroRNA technology to differentiate between squamous and non-squamous non-small cell lung cancer (NSCLC).
At present, the test is approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program and is expected to become available nationwide at the end of 2008. The diagnostic test utilizes a tumor tissue sample for MicroRNA testing with a sensitivity and specificity of over 90% for identification of squamous cell NSCLC.
Ask the Experts About Circulating Tumor DNA in the Management of Cancer
Ask the Experts About Circulating Tumor DNA (ctDNA) in the Management of Cancer
Tisotumab Vedotin – Promising in Advanced Cervical Cancer
Novel precision cancer medicine promising for treatment of advanced ovarian cancer.
Checkpoint Inhibitor Immunotherapy for Treatment of Advanced Cervical Cancer
Checkpoint inhibitor immunotherapy prolongs survival and delays recurrence in advanced cervical cancer.